文献速递其他结缔组织病

干燥综合征患者唾液腺上皮细胞促进B淋巴细胞存活与活化

Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation.
PubMed 文献 · Ann Rheum Dis · 2020-08-25

该研究探讨原发干燥综合征(pSS)患者唾液腺上皮细胞(SGECs)与B淋巴细胞的相互作用。结果显示pSS患者SGECs比对照组更强的诱导B淋巴细胞存活和活化能力,此效应依赖可溶性因子,来氟米特、BTK或PI3K抑制剂可部分降低B淋巴细胞活力,而单细胞因子靶向无效。

要点

  • pSS患者SGECs上调干扰素信号通路及免疫相关基因(HLA-DRA、IL-7、BAFF受体)。
  • pSS患者SGECs比对照组更强诱导B淋巴细胞存活,刺激后活化更明显且依赖可溶性因子。
  • 来氟米特、BTK或PI3K抑制剂部分降低B淋巴细胞活力,抗BAFF、抗APRIL、抗IL-6R、JAK1/3抑制剂或羟氯喹无效。

核心结论

  • pSS患者SGECs比对照组具有更强的诱导B淋巴细胞存活和活化的能力,此效应依赖可溶性因子。

研究设计与样本

  • 研究纳入符合2016年EULAR/ACR标准的pSS患者和对照,对唾液腺活检和血液中分离的SGECs及B淋巴细胞进行RNA-seq基因表达分析。
  • 将pSS和对照的SGECs与健康供者血液分选的B淋巴细胞共培养并刺激,进行Transwell和抑制实验。

主要发现

  • pSS患者SGECs基因表达分析显示干扰素信号通路和免疫应答相关基因(HLA-DRA、IL-7和B细胞活化因子受体)上调。
  • pSS患者唾液腺分选的B淋巴细胞中活化基因CD40和CD48上调。
  • SGECs诱导B淋巴细胞存活增加,且pSS患者SGECs的作用高于对照。
  • poly(I:C)刺激后,pSS患者SGECs比对照SGECs诱导更高的B淋巴细胞活化,该效应依赖可溶性因子。

关键数值与推荐

  • 抗B细胞活化因子、抗增殖诱导配体(APRIL)、抗白介素-6受体抗体、JAK1/3抑制剂或羟氯喹抑制无效。
  • 来氟米特、布鲁顿酪氨酸激酶(BTK)或磷脂酰肌醇3-激酶(PI3K)抑制剂部分降低该模型中B淋巴细胞活力。

临床怎么用

  • 提示pSS中靶向SGECs-B淋巴细胞交互可能为治疗方向,来氟米特、BTK或PI3K抑制剂或可部分抑制B淋巴细胞活力。
  • 单细胞因子靶向(如抗BAFF、抗APRIL、抗IL-6R)在该模型中未显示抑制效果。

局限性

  • 原文未报告研究样本量、具体统计值和P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Primary Sjögren's syndrome (pSS) is characterised by chronic hyperactivation of B lymphocytes. Salivary gland epithelial cells (SGECs) could play a role in promoting B-lymphocyte activation within the target tissue. We aimed to study the interactions between SGECs from patients with pSS or controls and B lymphocytes. METHODS: Patients had pSS according to 2016 European League Against Rheumatism/American College of Rheumatology criteria. Gene expression analysis of SGECs and B lymphocytes from pSS and controls isolated from salivary gland biopsies and blood was performed by RNA-seq. SGECs from pSS and controls were cocultured with B-lymphocytes sorted from healthy donor blood and were stimulated. Transwell and inhibition experiments were performed. RESULTS: Gene expression analysis of SGECs identified an upregulation of interferon signalling pathway and genes involved in immune responses (HLA-DRA, IL-7 and B-cell activating factor receptor) in pSS. Activation genes CD40 and CD48 were upregulated in salivary gland sorted B lymphocytes from patients with pSS. SGECs induced an increase in B-lymphocyte survival, which was higher for SGECs from patients with pSS than controls. Moreover, when stimulated with poly(I:C), SGECs from patients with pSS induced higher activation of B-lymphocytes than those from controls. This effect depended on soluble factors. Inhibition with anti-B-cell activating factor, anti-A proliferation-inducing ligand, anti-interleukin-6-R antibodies, JAK1/3 inhibitor or hydroxychloroquine had no effect, conversely to leflunomide, Bruton's tyrosine kinase (BTK) or phosphatidyl-inositol 3-kinase (PI3K) inhibitors. CONCLUSIONS: SGECs from patients with pSS had better ability than those from controls to induce survival and activation of B lymphocytes. Targeting a single cytokine did not inhibit this effect, whereas leflunomide, BTK or PI3K inhibitors partially decreased B-lymphocyte viability in this model. This gives indications for future therapeutic options in pSS.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Rivière E, Pascaud J, Tchitchek N, et al. Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation. Ann Rheum Dis. 2020. PMID: 32843324. doi:10.1136/annrheumdis-2019-216588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。